Thomas Schinecker, Roche CEO (Georgios Kefalas/EPA-EFE/Shutterstock )
October 19, 2023 06:22 AM EDTUpdated 06:33 AM
Pharma

Roche makes four pipeline changes on back of tri­al fail­ures, but sees path ahead for three ther­a­pies

Ayisha Sharma

News Reporter

Roche is re­work­ing its plans for a quar­tet of clin­i­cal pro­grams span­ning dif­fer­ent ther­a­peu­tic ar­eas and stages of de­vel­op­ment, but it may not be the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times